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Gatifloxacin eye drops are frequently used in eye infections. However such formulations
have a major drawback i.e. short duration of action and usually require 4e6 times in-
stallations daily. A chitosan coated niosomal formulation of gatifloxain was purposed to
show a longer retention time on eyes and subsequent reduction in dosing frequency.
Vesicles were prepared by solvent injection method using cholesterol and Span-60. An
extensive optimization of formulation was done using different ratios of cholesterol, Span-
60 and drug, revealed NS60-5 (cholesterol: span-60 50: 50 and drug content of 20 mg) to be
the optimized niosome formulation. NS60-5 had shown a highest entrapment efficiency of
64.9 ± 0.66% with particle size 213.2 ± 1.5 nm and zeta potential 34.7 ± 2.2 mV. Optimized
niosomes were also coated with different concentrations of chitosan and evaluated.
Permeation studies had revealed that optimized niosomes (86.77 ± 1.31%) had increased
the transcorneal permeation of Gatifloxacin more than two fold than simple drug solution
(37.19 ± 1.1%). Longer retention potential of the coated niosomes was further verified by
fluorescence microscopy. Study revealed that simple dye solution got easily washed out
with in 6 h. The uncoated niosomes (NS60-5) showed a longer retention (more than 6 h),
which was further enhanced in case of coated niosomes i.e. CNS60-1 (more than 12 h).
Antimicrobial studies had shown the better efficacy of CNS60-1 (zone of inhibition) when
compared to marketed formulation. The final chitosan formulation was found to have
shown better ocular tolerability as demonstrated by corneal hydration test histopathology
investigations.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).aceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India.
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One of the major problems encountered with most of the eye
drops is the rapid and extensive elimination of drugs from the
precorneal lachrymal fluid by solution drainage, lachryma-
tion, and non-productive absorption by the conjunctiva,
which may cause undesirable side effects [1]. In fact it has
been demonstrated through in vivo that 90% of the dose
cleared within 2 min for an instilled volume of 50 mL and
within 4min for an instilled volume of 10 mL [2]. Consequently,
the ocular residence time of conventional solutions is limited
to a few minutes, and the overall absorption of a topically
applied drug is limited to 1e10%.
Initial attempts to overcome the poor bioavailability of
topically instilled drugs typically involved the use of oint-
ments based on mixtures of white petrolatum and mineral
oils [3] and suspensions [4]. Because these vehicles have the
major disadvantage of providing blurred vision, they are
nowadays mainly used for either night time administration
or for treatment on the outside and edges of the eyelids [5].
Failures of the initial attempts lead to the advent of novel
approaches in the field of ocular drug delivery such as ocular
inserts, use of polymeric nanoparticles [6], cyclodextrin
complexes [7], collagen shields [8], liposomes [9], in-situ gels
[10,11], contact lenses [12], niosomes [13] etc. Niosomes
however are inexpensive, easy in preparation, stable and
reproducible systems. Niosomes and particularly niosomes
coated with bioadhesive materials can leads to a steady and
sustain release of drug into the ocular cavity without being
washed away frequently and could overcome the retention
problem of conventional eye drops. Chitosan, which is a well
explored and well understood polymer, offers many advan-
tages as a coating material such as: biodegradability, excel-
lent bioadhesive properties at physiological pH, penetration
enhancement, mild self antimicrobial action and
economical.
Gatifloxacin is an extensively used antibacterial for wide
variety of ocular infections. However a frequent dosing
(generally 4e8 times per day) is required to achieve the
effective concentration of it in eye. This leads to the need for
frequent installation of the drug into eye and hence patient
discomfort and patient non-compliance. Therefore, there is a
probable need of novel eye formulation for Gatifloxacin with
longer stay in eye and less frequent dosing.
Hence the present study emphasized to search for an
effective tool for solving low ocular retention problem of
Gatifloxacin by using the concept of bioadhesive niosomes.
The study involved development of chitosan coated nio-
somes, in-vitro characterization and investigating the safety
and efficacy of the developed formulation on in-vitro models.2. Materials and method
2.1. Materials
Gatifloxacin was a generous gift fromAristo Pharma, Mumbai.
Span 60, and cholesterol were purchased from central drug
house. Rhodamine- B andmediummolecular weight chitosanwith 75e85% deacetylation was purchased from Sigma
Aldrich. Goat eye cornea was obtained from local slaughter
house. Type-I, Millipore water was used for all the practical
purposes.2.2. Method of preparation of niosomes
The solvent injectionmethodwas used to prepare gatifloxacin
niosomes. Span-60, cholesterol and drug were mixed in
different ratios by weight (Table 1). For each ratio span 60 and
cholesterol were weighed accurately and dissolved in 5 ml of
chloroform. Drugwas then dissolved in the lipid solution. This
resulting solution was then taken in a syringe and injected
slowly into a beaker containing 20.0 ml of aqueous phase
(phosphate buffer pH 7.2) maintained at 60e70 C and agitated
slowly. As the lipid solution was injected slowly into aqueous
phase, vaporization of chloroform resulted into the formation
of niosomes.2.3. Characterization of niosome
2.3.1. Entrapment efficiency
The gatifloxacin entrapment capacity of niosomes was
determined by centrifugation method [14]. The entrapment
efficiency was determined after separating the unentrapped
drug by centrifugation at 4 C at 15,000 rpm for 2 h the nio-
somes were lysed using Triton-X 100 (0.1% v/v) and analysed
for drug content. Entrapment efficiency was expressed as
percentage of total drug entrapped.
The entrapment capacity was calculated using the
formula:
% Entrapment ¼ T C
T
 100
where,
T ¼ theoretical amount of drug that was added.
C ¼ amount of drug detected in the supernatant.
2.3.2. Size and size distribution
The niosome size and size distribution were determined by
Dynamic Light Scattering (DLS) technique, using a comput-
erized inspection system (Malvern Zetasizer, Nano-ZS, Mal-
vern) with DTS (nano) software®. For niosomes size
measurement, niosomal suspension was diluted with
distilled water and the measurements were conducted in
triplicate [15].
2.3.3. Zeta potential
Zeta potential of the niosomes was determined using Zeta
Sizer (Nano-ZS, Malvern).2.4. Preparation coated niosomes
Optimized niosomal formulationwas coatedwith bioadhesive
polymer chitosan for longer retention on cornea. Optimized
niosomal suspension was added with chitosan solution of
different concentrations (0.1, 0.2, 0.3mg/ml) and stirred for 2 h
with magnetic stirrer to get the chitosan coated niosomes
coded as CNS60-1, CNS60-2, and CNS60-3 respectively.
Table 1 e Compositions of different niosomes.
Formulation Code Composition
Drug (mg) Surfactant (mg) Cholesterol (mg) Chloroform (ml) Water (ml)
NS60-1 5 5 95 5 20
NS60-2 15 5 95 5 20
NS60-3 20 5 95 5 20
NS60-4 20 75 25 5 20
NS60-5 20 50 50 5 20
NS60-6 5 50 50 5 20
NS60-7 15 75 25 5 20
NS60-8 15 50 50 5 20
NS60-9 5 75 25 5 20
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Rheological properties of the niosomal formulations were
analysed by using Anton paar MCR 301 rheometer using cone
and platemeasuring geometry. The sampleswere subjected to
a shear rate variation of 0.1e100 sec1 and resulting shear
stress was noted.
2.6. Transcorneal permeation studies
The optimized niosomal formulation (uncoated) as well as
different coated niosomal formulations were subjected to
transcorneal permeation studies. The uncoated niosome
(NS60-5) formulation as well as drug suspension was also
evaluated for the same.
2.6.1. Treatment of cornea
Fresh whole eye balls of goat were brought from the local
butcher's shop to the laboratory in cold normal saline (4 C).
The cornea along with 2e4 mm of sclera tissue was excised
and was washed with cold normal saline. The washing of
cornea was continued till washings tested negative for pro-
teins as estimated by Folin's Phenol reagent and it gives zero
UV absorbance at 296.5 nm using 0.9% normal saline as blank.
Throughout the preparation great care was taken to avoid
physical trauma to the tissue [13].
2.6.2. Preparation of artificial tear fluid
Artificial tear fluid (ATF), pH 7.4, was used in all the trans-
corneal permeation studies which consist of: sodium bicar-
bonate 0.200 g, sodium chloride 0.670 g, calcium chloride
dihydrate 0.008 g, and purified water q.s. 100 g [16].
2.6.3. Permeation experiment
Modified Franz Diffusion Cell with a diffusion area of
0.785 cm2 and a receiver volume of 15 ml were used in passive
diffusion studies and all experiments were conducted in
triplicate. ATF pH 7.4 was used as the receiver medium.
Freshly excised treated cornea was fixed between donor and
receptor compartments of an all-glass modified Franz diffu-
sion cell in such a way that its epithelial surface faced the
donor compartment. Donor compartment was fixed on the
cornea. After filling the donor compartment with formulation
(niosomal formulations, free drug suspension, or marketed
formulation) with equivalent quantities of drug, samples
(1ml) were withdrawn through sampling port of the Franz cellat predetermined time intervals over 24 h and analyzed by UV
spectrophotometer at 296.5 nm. The receptor phase was
immediately replenished with equal volume of fresh phos-
phate buffer. Sink condition was maintained throughout the
experiment. At the end of each permeation experiment the
integrity of the cornea was checked microscopically for the
presence of any pore or tearing.
2.7. Shape and surface morphology of the niosomes
Niosomes were visualized using a Philips TEM CM 12 Electron
Microscope, with an accelerating voltage of 100 kV. Samples
were negatively stained with a 1% aqueous solution of phos-
photungstic acid. A niosomal suspension containing drug was
dried on a microscopic carbon-coated grid for staining. The
excess solution was removed by blotting. After drying, the
specimen was viewed under the microscope at a 100 k fold
enlargement.
2.8. Bioadhesion testing
The bioadhesive potential of the optimized coated niosomes,
uncoated niosomes, marketed formulation (Zymar®) was
evaluated bymethod reported by Bachhav and Patravale, 2009
[17]. An agar plate (1% w/w) was prepared in pH 7.2 phosphate
buffer. Test samples of 2.5 ml were placed at the center of
plate. After 5 min, the agar plate was attached to an IP disin-
tegration test apparatus and moved up and down in pH 7.2
phosphate buffer at 37 ± 1 C. The sample (formulation with
dye) on the plate was immersed into the solution at the lowest
point and was out of the solution at the highest point. Dye
loaded formulations were prepared by adding 5 mM Rhoda-
mine B in organic phase (Chloroform) in place of drug during
preparation of niosomes and following procedure similar to
drug loaded niosomes. The residence time of the test samples
on the plate was noted by visual appearance of the formula-
tion over the plate.
2.9. Corneal retention study by fluorescence microscopy
Fluorescence microscopic evaluations were done to deter-
mine the corneal retention and permeation of the coated and
uncoated niosomal formulation. Rhodamine Bwas used to tag
the formulations. Corneal samples were subjected to perme-
ation study with formulation containing fluorescent dye and
fixed for visualization after 2 h, 6 h and 12 h. The blank sample
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 2 2e3 3 0 325consisting of rhodamine solution in water was similarly
applied on a corneal sample. All the corneal sample slides
were prepared and fixed in 10% formic acid to washout the
applied extra fluorescent dye from the corneal surface before
its microscopic evaluation. Slides were then evaluated using
fluorescentmicroscope at an excitation wavelength of 540 nm
and emission wavelength of 625 nm.
2.10. Evaluation of anti-microbial potency of niosomal
formulation
Anti-microbial potency of the niosomal formulation was
compared with the marketed formulation using antimicrobial
assay. Nutrient agar plates were inoculated with B. subtilis
suspension. Standard wells were bored into these plates and
pouredwith equal amount of samples containing sterilewater
(control), niosomal placebo formulation, optimized niosomal
formulation (CNS60-1) and marketed formulations separately
at concentration of 0.05 mg/ml, 0.1 mg/ml, and 0.2 mg/ml.
Plates were incubated for 48 h at 34e37 C. At the end of the
experiment the zone of inhibition for different treatments
were noted.
2.11. Toxicity studies
Safety prospective of the formulation was investigated by
toxicity studies. The following tests were carried out to eval-
uate any untoward reaction of the formulation on eye cornea:
2.11.1. Corneal hydration test
Goat corneas from permeation studies were used for the
determination of corneal hydration. At the end of the exper-
iment, each cornea (freed from adhering sclera) was weighed,
soaked in 1 ml methanol, dried overnight at 90 C, reweighed.
From the difference in weights, corneal hydration calculated
[18].
2.11.2. Histological studies
Toxic effects of the optimized niosomal formulation were
investigated using histological studies. Goat cornea was kept
in niosomal suspension, simple drug suspension, normal sa-
line (Negative control), and saturated KCl solution (Positive
control). Cornea was removed from their respective medium
at different time interval (1 h, 6 h and 12 h) and fixed in 10%
formalin solution. Properly fixed and stained slides were
prepared from the samples and microscopically evaluated for
cell disruption and toxic effects.
2.11.3. Effect of niosome formulation corneocytes: biochemical
estimation
A comparative toxicity study was carried out to get an insight
of the tissue interference by niosomes on corneocytes. The
assembly for transcorneal permeation was set as described
using goat cornea. The donor compartments were filled with
aqueous suspension of optimized niosomes (10 mg/ml of dried
niosomes) and equivalent amount of span-60: cholesterol
mix, separately for 60 min with Tyrode solution in both the
compartments. Normal saline and Triton X 100 (1%) were
employed as negative and positive controls respectively. Post
60 min the samples were taken from the receptorcompartment and evaluated by using Accurex biomedical kit
for LDH assay.2.12. Statistical analysis
Analysis of variance (KruskaleWallis or One-way ANOVA)
along with multiple comparison test (Student-Newman-Keuls
Method) and t-test (for two samples) were employed by Sig-
maStat® 3.5 software at P < 0.05.3. Results and discussions
3.1. Optimization of uncoated niosomes
The optimization of the uncoated niosomes that were pre-
pared by solvent evaporation was done on the basis of
entrapment efficiency, size and zeta potential. The entrap-
ment efficiency of the niosomes was found to get increased
with increase in cholesterol concentration (Table 2). As gati-
floxacin is lipophilic in nature, increases in lipophilic
component (cholesterol) lead to more entrapment [19] in the
niosomes. Excess of surfactant lead to leakage of drug from
the vesicles and hence a lower entrapment was observedwith
higher concentrations of span-60. A maximum entrapment
efficiency of Gatifloxacin was observed with NS60-5
(64.9 ± 0.66%).
Size of the vesicles was found vary non-significantly with
the surfactant concentration from 5 to 50%. However a sharp
increase in particle size was observed with 75% of span-60
(Table 2). The higher concentration may be having destabi-
lizing effect on the vesicles, which lead to a very large particle
size. Smallest size was observed for formulation NS60-5
(213.2 ± 1.5 nm).
Zeta-potential of all the formulations were found to be
negative. This might be due to the presence of free carboxyl
groups in cholesterol and surfactant molecule. There was no
statistically significant difference observed between the zeta-
potential values of different formulations (Table 2). The zeta-
potential value suggested sufficient kinetic stability of the
niosomes. Highest zeta-potential was observed with NS60-5
(34.7 ± 2.2 mV).
The comparative analysis of particle size, zeta-potential
and entrapment efficiency of different niosomal formula-
tions had suggested that Formulation NS60-5 was the best
optimized formulation. NS60-5 contained surfactant: choles-
terol (50:50) and drug 20 mg. NS60-5 was considered for
further formulation development into coated niosomes.3.2. Optimization of coated niosomes
The optimized uncoated niosomal formulation (NS60-5) was
coated with solutions of different chitosan concentrations
and evaluated for their size, zeta-potential, viscosity and
transcorneal permeation.
An increase in particle size was observedwith the chitosan
concentration for the coating of niosomes. The original size of
uncoated niosomes was 213.2 ± 1.5 nm which got subse-
quently increased to 218.2 ± 2.3, 276.5 ± 1, and 296.9 ± 4.1 nm
Table 2 e Comparative characters of different uncoated niosomes.
S.N. Formulation Surfactant: Cholesterol Zeta potential (mV) ± SD Size (nm) Entrapment (%)
1 NS60-1 5:95 30 ± 1.1 276.5 ± 1 53.1 ± 2.1
2 NS60-2 5:95 31.2 ± 2.2 218.2 ± 2.3 60.1 ± 0.9
3 NS60-3 5:95 28.1 ± 1.2 296.9 ± 4.1 64.2 ± 0.5
4 NS60-4 75:25 29 ± 2.3 249 ± 2.2 43.21 ± 0.54
5 NS60-5 50:50 34.7 ± 2.2 213.2 ± 1.5 64.9 ± 0.66
6 NS60-6 50:50 31.4 ± 2.3 403.7 ± 2.6 33.1 ± 0.23
7 NS60-7 75:25 32.1 ± 2.1 1252 ± 12.9 29.34 ± 0.45
8 NS60-8 50:50 28.6 ± 1.8 585.5 ± 6.3 39.8 ± 0.91
9 NS60-9 75:25 31.1 ± 1.2 1370 ± 9.9 21.1 ± 1.2
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tively (Table 3).
A very good correlation was observed with the percentage
of chitosan coating and zeta potential of the niosomes. Orig-
inally the zeta-potential of the uncoated niosomes (NS60-5)
was 34.7 mV. However, niosome particles were found to
have carried a positive charge after coating with chitosan.
Hence, this can be concluded that chitosan get adsorbed on
the surface of the negatively charged niosomes and imparted
an overall positive surface charge to them. Further, an in-
crease in zeta-potential was observed with the increase in
concentration of chitosan (Table 3).
All the niosomal formulations were found to have shown
non-Newtonian behaviour (shear thinning). There relative
yield point values gave an indication that chitosan coated
niosomes with higher concentration of coating had higher
viscosity (Table 3). Furthermore, it was observed that on
coating the niosomes with chitosan initially an increase in
total drug permeation (89.62%) was found with 0.1% coating
(CNS60-1). This might be attributed to bioadhesive as well as
permeation enhancing action of chitosan. Chitosan was re-
ported to have a property of loosening the tight junctions of
the cell layers [20]. However, on further increase in chitosan
concentration a sharp decrease was observed in permeation.
The increase in overall viscosity of the formulation at higher
chitosan concentration might be a possible reason for that.
Over all formulation CNS60-1 was found to be a potential
candidate as it had shown a better permeation profile and
sufficiently low viscosity than other formulations. Higher
viscosity of an eye formulation may lead to difficulty in
administration as well as smudging and blurring of vision.3.3. Shape and surface morphology of niosomes
Pictures from transmission electron microscope showed clear
structural differences between coated and uncoated niosomal
formulations (Fig. 1a and b). Uncoated niosomes (NS60-5) were
found to be circular in size with well defined boundaries. OnTable 3 e Comparative characters of different coated niosome
S.N. Formulation Chitosan concentration (%) Size (nm) Zet
1 NS60-5 Uncoated 213.2 ± 1.5
2 CNS60-1 0.1 218.2 ± 2.3
3 CNS60-2 0.2 276.5 ± 1
4 CNS60-3 0.3 296.9 ± 4.1the other hand a clear coating layer with uneven boundaries
can be seen over the chitosan coated niosomes (CNS60-1).
3.4. Transcorneal permeation
Transcorneal permeation profile of the optimized formulation
(CNS60-1) was compared with free drug suspension and mar-
keted gatifloxacin eye drop (Zymar ®). Due to the low aqueous
solubility, transcorneal permeation of gatifloxacin was found
to be very slow and incomplete from drug suspension. Only
35.03 ± 1.1% of the drug was able to permeate in 24 h from the
drug suspension. On the other hand therewas amore complete
permeation of gatifloxacin fromniosomal formulation (NS60-5)
81.73 ± 2.1% of drug was permeated in 24 h (Fig. 2). The coated
niosomal formulation (CNS60-1) has also shown an enhanced
permeation (86.77 ± 1.31%) in 24 h. This observation could be
attributed to the permeation enhancement effect of the nio-
somes. Furthermore, it was observed that permeation from the
free drug suspension was concentration dependent, and a
decrease in percentage permeationwas observedwith increase
in time. However, permeation of drug from the niosomes was
found to be concentration independent. This could be due the
dominance of hydrotaxis forces for the transport of the nio-
somes through the cornea over the concentration gradient due
to the presence of lecithin [21]. Hence, if retained for a longer
time over the cornea, niosomes can provide a sufficient con-
centration (minimum inhibitory concentration) of drug over
the period of time.
3.5. Bioadehesion testing
The bioadhesive potential of chitosan coated niosomal
formulation (CNS60-1) was compared to marketed formula-
tion as well as uncoated niosomal formulation (NS60-5) by
using the in house bioadhesion assembly (Fig. 3). The results
clearly indicate that the chitosan coated niosomes had the
longer retention time (176 ± 5.5 min) over the agar plate than
marketed formulation (2 ± 0.5 min) and uncoated niosomal
formulation (28 ± 2.25 min).s.
a potential (mV) ± SD Yield point (Pa) % Permeated (24 h)
34.7 ± 3.2 1.2 81.73 ± 1.29
22.3 ± 0.3 1.9 89.62 ± 2.68
27.5 ± 0.34 3.6 76.68 ± 1.11
33.3 ± 0.11 4.5 68.95 ± 3.31
Fig. 3 e In-house bioadhesion testing assembly.
Fig. 1 e TEM photographs of niosomal formulations (a)
NS60-5 (uncoated), and (b) CNS60-1 (coated).
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The fluorescent study with rhodamine-b dye solution showed
initially fluorescence (Fig. 4A1), which subsequently dis-
appeared with time (Fig. 4A2 and A3). Dye solution had poor
retention over the goat cornea which represents normal drug
solution. In contrast to this use of niosomal formulation NS60-
5, had increased the overall retention time of the dye in theFig. 2 e Transcorneal permeation profile.corneal tissues. There was significant amount of fluorescence
left in the tissues even at 6th hour of treatment (Fig. 4B2).
However, at the 12 h there was very less amount of fluores-
cence left in the tissues. On the other hand chitosan coated
niosomal formulation CNS60-1, had further extended the dye
retention in the corneal tissues. A significant amount of fluo-
rescence was left in the tissues even at 12th hour (Fig. 4C3) as
compared to uncoated niosomal formulation NS60-5 (Fig. 4B3).
Therefore it can be safely concluded that chitosan coated nio-
some formulation (CNS60-1) had good retention capacity in
corneal tissues, and can be efficiently prolong the retention of
gatifloxacin in eye for the reduction of dosing frequency.
3.7. Evaluation of anti-microbial potency of niosomal
formulation
An antimicrobial study was performed to evaluate the relative
potency of the niosomal formulation. The study was per-
formed using three different concentrations of gatifloxacin
(0.05, 0.1, and 0.2 mg/ml) in niosomal formulations and mar-
keted eye drop (Table 4). Concentration higher than 0.2 mg/ml
had shown overlapping of zone of inhibitions. The placebo
niosomal formulations had shown a weak antimicrobial ac-
tivity itself. This might be due to presence of chitosan in the
formulation which was itself reported to carry antimicrobial
effects. There was an increase in zone of inhibition with
increased concentration of gatifloxacin in CNS60-1 niosome
formulation. It was also found to be more potent than mar-
keted eye drop at every concentration. It was observed with
the marketed formulation that initially there was an increase
in zone of inhibition with the increase in concentration.
Fig. 4 e Fluorescent images showing permeation through the goat cornea (Dye solution) [(A1) 2 hours, (A2) 6 hours, and
(A3) 12 hours], (uncoated niosomes, NS60-5) [(B1) 2 hours, (B2) 6 hours, and (B3) 12 hours], and (coated niosomes CNS60-1)
[(C1) 2 hours, (C2) 6 hours, and (C3) 12 hours].
Table 4 e Zone of inhibition of placebo CNS60-1, CNS60-1
and marketed formulation.
Concentration
of gatifloxacin
Mean zone of inhibition of B. Subtilis (mm)a
Control Plecebo
CN60-1
CN60-1 Marketed
eye drop
0.05 mg/ml 5 6 17 10
0.1 mg/ml 5 7 20 16
0.2 mg/ml 5 7 28 17
a Size of well (5 mm) was included in all the measurements.
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change was observed in the zone of inhibition. This could be
attributed to the lowdiffusion of the drug through the nutrient
agar. A lower solubility of gatifloxacin found to have limited
its diffusion after an optimum concentration. On contrary the
niosomes had resulted in better permeation of the drug, and
there was constant increase in zone of inhibition with in-
crease in drug concentration.
3.8. Toxicity studies
Normal cornea has a hydration level of 75e80% [22]. Corneal
hydration observed in the present experiments was between 76
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 2 2e3 3 0 329and 79%, indicating no damage to cornea. Lack of toxicity of the
optimized chitosan coated formulation was further demon-
strated by histological studies (Fig. 5). KCl solution (positive
control) had shown marked damage to the corneal tissues
(Fig. 5A). An initial swelling was observed with KCl solution inFig. 5 e Histological study of goat cornea A. KCl solution, Bfirsthourwhich lead tosubsequentdamageof corneal cell layers
till 6th and 12th hour. Normal saline was taken as a negative
control in the study and corneal tissues showednodamagewith
it (Fig. 5B). There were no toxic responses were seen with drug
suspension and CNS60-1 formulation (Fig. 5C and D).. Normal saline, C. Drug suspension, and D. CNS60-1.
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Fig. 6 e Influence niosome formulation on LDH release
(SD, n¼3).
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estimation of LDH. High concentrations of LDH are often asso-
ciated with the tissue injury. Thus, the estimation of LDH is
often employed as biochemical estimation of toxicity [23,24].
Triton X-100 treatment showed amarked release of LDH due to
tissue destruction, while LDH release was minimal in case of
normal saline (Fig. 6). Furthermore, high LDH release was also
observed in case of free span-60-cholestrol mix. On contrary,
niosome formulation had significantly lower LDH release
(P < 0.05). We have demonstrated in our previous work that
surfactants bound to vesicular system had lower potential to
cause cellular damage than free surfactant molecules [24].
Thus, comprehensive toxicological investigation revealed that
thedevelopedniosomal formulationshad lower toxic potential.4. Conclusion
The novel niosomal formulation of gatifloxacin was found to
be capable of increasing the corneal retention of the drug. Also
there was a significant enhancement of transcorneal perme-
ation by the formulation. Hence this novel formulation was
found to be a good replacement for conventional eye drops
with decreased dosing frequency and an effective drug levels
in eyes. The future perspectives include study of effects of
different bioadhesives, pharmacokinetic studies and clinical
trials for developing a clinically viable formulation.r e f e r e n c e s
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